EN DE
Watch Sosei Group Corporation for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Sosei Group Corporation (SOLTF) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Sosei Group Corporation stock $8.58, price $10.50, that is 18.3% below the price, quality 30 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Based in Japan

SG Sosei Group Corporation logo Thin data Nov 10, 2026

Sosei Group Corporation

SOLTF · US
Expensive, weak quality

Our calculation puts a fair price 18% below what the stock costs today.

Mixed Growth (revenue 5y +27.4 %/yr in JPY)
Moderate debt
Mixed vs. peers (4/9)
Revenue last quarter 9% below a year ago.
Fair value $8.58 · Overvalued
Quality 30/100
Loss-making · -23.3% net margin (TTM)
Negative free cash flow
Narrow moat 12/100
Thin data
Estimate⚠ Thinly traded
Watch Sosei Group Corporation for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$59.26 $4.91 Fair Value $8.58 Jul 2015 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $4.91 – $59.26 · fair‑value band $6.43 – $10.72 · the $10.50 price screens above the $8.58 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 10, 2026.

Follow Sosei Group in your weekly email

Every Wednesday you see whether Sosei Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Nxera Pharma Co., Ltd. operates as a biopharmaceutical company, engages in drug discovery and development in Japan, the United States, Germany, Switzerland, Bermuda, the United Kingdom, and internationally.

Show moreShow less

The company offers NxWave, a GPCR-targeted structure-based drug discovery platform; PIVLAZ for the cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aSAH; and QUVIVIQ for insomnia.

It develops NBI-1117568, an muscarinic M4 agonist in phase 3 trial for schizophrenia, dementia and other neuropsychiatric disorders; ORX750, an OX2 agonist for narcolepsy, idiopathic hypersomnia, and other sleep-wake disorders; NBI-1117570, a dual muscarinic M1/M4 agonist; and HTL0039732, an EP4 antagonist immunotherapy drug.

The company's products in phase 1 trial include PF-07054894, a CCR6 antagonist and NXE0033744, an EP4 agonist for inflammatory bowel disease; PF-07258669, a MC4 antagonist for anorexia; NBI-1117569, a muscarinic M4-preferring agonist, and NBI-1117567, a muscarinic M1 agonist for major central nervous system disorders; TMP-301, a mGlu5 NAM for substance use disorders; and NXE0048149, a GPR52 agonist for schizophrenia.

Its products in preclinical trial comprise KY1051, a CXCR4 mAb for immuno-oncology; and NXE0027477, a GPR35 agonist for inflammatory bowel disease and GI disorders. The company also develops other discovery-stage drugs.

It has strategic collaborations with Tempero Bio, Pharmenable Therapeutics, Antiverse, Sanofi, Cancer Research UK, Centessa Pharmaceuticals, Lilly, AbbVie, Genentech, Pfizer, Neurocrine Biosciences, Antiverse, and Novartis International AG. The company was formerly known as Sosei Group Corporation.

Nxera Pharma Co., Ltd. was incorporated in 1990 and is headquartered in Minato, Japan.

Stock analysis

Sosei Group Corporation (SOLTF) currently trades at $10.50, while our estimate is $8.58, 18% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $6.43 (bear) to $10.72 (bull), the price of $10.50 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Sosei Group Corporation reported revenue of ¥29.6B in FY2025 versus ¥17.7B in FY2021, a compound +13.7%/yr. Reported net income was −¥12.5B in FY2025.

Key figures

Market cap $959M Small · P/S ratio 0.02 · EPS (TTM) $−0.5700 · Net margin −42.3% · Return on equity −11.9% · Return on assets (EBIT) −1.7% (5-year average) · Operating margin −17.8% · Revenue (TTM) ¥33.4B.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 16% below its 52-week high and 114% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −18%, SOLTF screens richer than that median.

Fair Value

Bear $6.43 Fair Value $8.58 Bull $10.72
Price $10.50 · Downside -18.3%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 30/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 7
How much profit the company makes from its sales and capital
Quality Growth 26
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 43
Debt, balance sheet and risk of trouble
Investment 79
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 84
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 87
Distance to the 52-week high, does not count
New shares 58
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+2.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.4%
Start year 2020 (pandemic). Over 10 years: +13.8% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
10.5% (2020) → −27.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

SOLTF screens overvalued: fair value 18% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Sosei Group Corporation with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 30 · Bottom 25%
Fair Value upside −18.3% · Above median
Profitability
Return on assets −9.3% · Above median
Net margin (12 months) −23.3% · Below median
Operating margin (12 months) −17.8% · Below median
Growth and dividend
Revenue growth (quarter YoY) −9.4% · Below median
Balance sheet
Debt / equity 0.77× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 2.49× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 4.56× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)9 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)61 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs SOLTF
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs SOLTF
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs SOLTF
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs SOLTF
argenx SE ARGX $971.55 $908.40 −7% vs SOLTF
CSL Limited CSL A$201.68 A$181.40 −10% vs SOLTF
Moderna, Inc MRNA $250.83 $158.70 −37% vs SOLTF
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs SOLTF
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs SOLTF
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs SOLTF

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Sosei Group Corporation: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Sosei Group Corporation Fair Value". https://www.fairvalue-calculator.com/stock/SOLTF

Frequently asked questions

Is Sosei Group Corporation (SOLTF) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $8.58 versus a price of $10.50, about 18% lower (overvalued).
What is the fair value of SOLTF?
Our estimate for Sosei Group Corporation is $8.58 (as of Nov 10, 2026), built from audited fundamentals. The current price: $10.50.
What is the quality score of SOLTF?
Sosei Group Corporation has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sosei Group Corporation (SOLTF)?
Our calculated price target is the estimate of $8.58 (as of Nov 10, 2026). Cautious scenario $6.43, optimistic scenario $10.72. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Sosei Group Corporation stock forecast for 2026?
Our estimate puts fair value at $8.58, about 18% lower versus a price of $10.50 (overvalued). Cautious scenario $6.43, optimistic scenario $10.72. The calculation is refreshed regularly with new filings.
What is the revenue of Sosei Group Corporation (SOLTF)?
Sosei Group Corporation reported trailing-twelve-month revenue of about ¥33.4B (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Sosei Group Corporation (SOLTF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sosei Group Corporation it is $8.58 per share (as of Nov 10, 2026), against a price of $10.50.
Is Sosei Group Corporation stock overvalued or undervalued in 2026?
As of Nov 10, 2026, SOLTF trades above its calculated fair value: price $10.50, fair value $8.58, a gap of about −18% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SOLTF?
No. The price is what the market pays today ($10.50); the fair value is what the company's own numbers justify ($8.58). For Sosei Group Corporation the two are $1.92 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sosei Group Corporation worth?
The market values Sosei Group Corporation at about $959M (market capitalisation, as of Nov 10, 2026). Per share that is $10.50; our models calculate a fair value of $8.58 per share.
What do the bullish and bearish scenarios say about SOLTF?
Our models span a range for Sosei Group Corporation: cautious scenario $6.43, base $8.58, optimistic $10.72 per share (as of Nov 10, 2026, price $10.50). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Sosei Group Corporation (SOLTF)?
Balance-sheet figures for Sosei Group Corporation (as of Nov 10, 2026): return on equity −11.9%, debt of 0.77 per unit of equity. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is SOLTF from its 52-week high?
Sosei Group Corporation trades at $10.50, about 16% below its 52-week high of $12.50 and 114% above the low of $4.91 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $8.58 is for.
Which stocks are comparable to Sosei Group Corporation?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sosei Group Corporation stock attractive at the current price?
The data as of Nov 10, 2026: price $10.50, calculated fair value $8.58 (−18%), Quality Score 30/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Sosei Group Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sosei Group Corporation (SOLTF)?
The closing price on Nov 6, 2026 was $10.50. Our estimate is $8.58, about 18% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sosei Group Corporation right now?
Weak quality (30/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Sosei Group Corporation

How large is the market capitalisation of Sosei Group Corporation (SOLTF)?
The market capitalisation of Sosei Group Corporation is $959M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sosei Group Corporation (SOLTF)?
The price-to-sales ratio of Sosei Group Corporation is 0.02 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sosei Group Corporation (SOLTF)?
Earnings per share at Sosei Group Corporation are $−0.5700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Sosei Group Corporation (SOLTF)?
The net margin of Sosei Group Corporation is −42.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sosei Group Corporation (SOLTF)?
The return on equity (ROE) of Sosei Group Corporation is −11.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sosei Group Corporation (SOLTF)?
On an EBIT basis the return on assets of Sosei Group Corporation is −1.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sosei Group Corporation (SOLTF)?
The operating margin of Sosei Group Corporation is −17.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sosei Group Corporation (SOLTF)?
Revenue at Sosei Group Corporation is growing −9.4% versus a year earlier (3y avg +23.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sosei Group Corporation (SOLTF)?
Earnings per share at Sosei Group Corporation are growing +27.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Sosei Group Corporation (SOLTF) generate?
The free cash flow of Sosei Group Corporation is −¥3.1B (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Sosei Group Corporation (SOLTF) carry?
The net debt of Sosei Group Corporation is ¥37.0B (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Sosei Group Corporation in the live analysis

One click puts Sosei Group Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.